OBJECTIVE: To report a newly recognized adverse effect of oral moxifloxacin. DESIGN: Observational case reports. PARTICIPANTS: Five patients who used oral moxifloxacin therapy. MAIN OUTCOME MEASURES: In five patients, a uveitis-like episode followed oral moxifloxacin therapy, afterwards they experienced photophobia. At slitlamp investigation, the patients showed almost complete iris transillumination, not restricted to one sector, and persistent mydriasis of the pupil, with no reaction to light and no near reflex. Follow-up of 3 years in one of the patients showed no change of symptoms. Only in one patient, with a history of anterior uveitis, an anterior chamber tap was positive for herpes simplex genome. Only after the use of moxifloxacin did she experience continuous photophobia. CONCLUSIONS: Iris transillumination and sphincter paralysis is a newly recognized adverse effect of oral moxifloxacin therapy.
OBJECTIVE: To report a newly recognized adverse effect of oral moxifloxacin. DESIGN: Observational case reports. PARTICIPANTS: Five patients who used oral moxifloxacin therapy. MAIN OUTCOME MEASURES: In five patients, a uveitis-like episode followed oral moxifloxacin therapy, afterwards they experienced photophobia. At slitlamp investigation, the patients showed almost complete iris transillumination, not restricted to one sector, and persistent mydriasis of the pupil, with no reaction to light and no near reflex. Follow-up of 3 years in one of the patients showed no change of symptoms. Only in one patient, with a history of anterior uveitis, an anterior chamber tap was positive for herpes simplex genome. Only after the use of moxifloxacin did she experience continuous photophobia. CONCLUSIONS:Iris transillumination and sphincter paralysis is a newly recognized adverse effect of oral moxifloxacin therapy.
Authors: David M Hinkle; Nicole A Kruh-Garcia; Jonathan N Kruh; Carolyn Broccardo; Priyanka Doctor; C Stephen Foster Journal: Open Ophthalmol J Date: 2017-06-12